Tarsus Pharmaceuticals (TARS) Competitors $74.95 +5.12 (+7.33%) Closing price 04:00 PM EasternExtended Trading$74.93 -0.02 (-0.03%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. QGEN, ELAN, BBIO, VRNA, RVMD, MRUS, RNA, GRFS, CYTK, and RYTMShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Its Competitors QIAGEN Elanco Animal Health BridgeBio Pharma Verona Pharma PLC American Depositary Share Revolution Medicines Merus Avidity Biosciences Grifols Cytokinetics Rhythm Pharmaceuticals Tarsus Pharmaceuticals (NASDAQ:TARS) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk. Which has stronger earnings & valuation, TARS or QGEN? Qiagen has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M17.29-$115.55M-$2.33-32.17Qiagen$1.98B5.34$83.59M$1.6928.14 Is TARS or QGEN more profitable? Qiagen has a net margin of 18.30% compared to Tarsus Pharmaceuticals' net margin of -31.13%. Qiagen's return on equity of 14.77% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-31.13% -32.36% -21.04% Qiagen 18.30%14.77%8.87% Which has more volatility and risk, TARS or QGEN? Tarsus Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Does the media refer more to TARS or QGEN? In the previous week, Qiagen had 4 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 9 mentions for Qiagen and 5 mentions for Tarsus Pharmaceuticals. Qiagen's average media sentiment score of 0.91 beat Tarsus Pharmaceuticals' score of 0.54 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TARS or QGEN? Tarsus Pharmaceuticals presently has a consensus target price of $66.67, indicating a potential downside of 11.05%. Qiagen has a consensus target price of $49.40, indicating a potential upside of 3.89%. Given Qiagen's higher possible upside, analysts plainly believe Qiagen is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50Qiagen 0 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do insiders & institutionals believe in TARS or QGEN? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryQiagen beats Tarsus Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.16B$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-32.1722.9285.3627.35Price / Sales17.29268.92516.10196.40Price / CashN/A46.9537.5761.53Price / Book12.7710.5512.426.82Net Income-$115.55M-$52.58M$3.32B$276.80M7 Day Performance7.46%1.09%0.97%0.26%1 Month Performance51.14%16.09%10.70%8.29%1 Year Performance101.05%18.41%76.19%35.59% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals0.6837 of 5 stars$74.95+7.3%$66.67-11.1%+91.4%$3.16B$182.95M-32.1750QGENQIAGEN4.3804 of 5 stars$46.99+0.4%$49.40+5.1%+10.8%$10.40B$1.98B27.765,765ELANElanco Animal Health2.78 of 5 stars$20.68+0.2%$18.33-11.3%+41.0%$10.25B$4.44B24.059,000Analyst RevisionBBIOBridgeBio Pharma4.1045 of 5 stars$54.61+3.3%$63.94+17.1%+119.2%$10.11B$221.90M-13.35400VRNAVerona Pharma PLC American Depositary Share1.4594 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.20B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.1145 of 5 stars$46.58-0.3%$74.64+60.2%-3.5%$8.73B$11.58M-10.35250MRUSMerus0.8787 of 5 stars$94.270.0%$93.12-1.2%+81.8%$7.13B$56.23M-17.1437RNAAvidity Biosciences1.9826 of 5 stars$46.18-1.7%$68.32+47.9%+3.0%$6.86B$10.90M-12.97190GRFSGrifols3.7631 of 5 stars$9.61-3.4%$10.30+7.2%+11.7%$6.84B$7.81B8.2123,822Positive NewsCYTKCytokinetics3.5746 of 5 stars$60.64+6.4%$76.64+26.4%+12.0%$6.82B$18.47M-11.89250RYTMRhythm Pharmaceuticals3.0512 of 5 stars$97.86-1.2%$106.64+9.0%+109.4%$6.58B$130.13M-32.51140 Related Companies and Tools Related Companies QIAGEN Alternatives Elanco Animal Health Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Merus Alternatives Avidity Biosciences Alternatives Grifols Alternatives Cytokinetics Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
